NEW YORK (GenomeWeb News) – Microfluidics company RainDance Technologies said today that it has joined a French consortium to develop a microfluidic system for use in quantitative high-throughput screening of potential drug compounds.
In addition to the Lexington-Mass.-based company, the dScreen Consortium includes the drug-maker Sanofi-Aventis and the Institute for Science and Supramolecular Engineering at Louis Pasteur University of Strasbourg. The consortium was founded with assistance from the Alsace BioValley cluster.
One of the consortium’s goals is to develop a microfluidic system for quantitative high-throughput screening of bio-active compounds using purified targets and cell-based assays. Such a system would enable researchers to gauge dose-response curves for compounds in a chemical library.
Another effort will be to develop a new system for storing compounds in which each compound will be stored in droplets using a microfluidic device.
"The simplicity, speed and minute volume of our technology replace current complex automation solutions in high-throughput screening,” RainDance Technologies CEO Chris McNary said in a statement. “Our technology will process 10 million droplets per hour on a single benchtop instrument, dramatically accelerating the drug discovery process while conserving precious screening compounds."